What are the recommended management steps for a 67-year-old woman with a dual-energy X-ray absorptiometry (DEXA) showing normal lumbar spine and left total hip bone density, osteopenia at the left femoral neck (T-score –1.7) and a 10-year Fracture Risk Assessment (FRAX) of 5.7% for major osteoporotic fracture and 0.8% for hip fracture?

Management Recommendations for 67-Year-Old Woman with Osteopenia

This patient does NOT require pharmacologic treatment at this time based on her FRAX scores (5.7% major osteoporotic fracture risk, 0.8% hip fracture risk), which fall well below treatment thresholds, despite having osteopenia at the femoral neck. 1

Treatment Decision Algorithm

Step 1: Assess Treatment Thresholds

Your patient's fracture risk does not meet criteria for pharmacologic intervention:

• 10-year hip fracture risk: 0.8% (threshold: ≥3%)
• 10-year major osteoporotic fracture risk: 5.7% (threshold: ≥20%)
• T-score: -1.7 (osteopenia range, not osteoporosis which is ≤-2.5)

Pharmacologic treatment should be considered when FRAX shows 10-year risk of major osteoporotic fracture ≥20% OR hip fracture risk ≥3%. 1 This patient meets neither threshold. The 2020 AACE guidelines similarly indicate treatment for those with "high FRAX fracture probability," defined as major osteoporotic fracture risk ≥20% or hip fracture risk ≥3%. 2

Step 2: Implement Non-Pharmacologic Interventions (Essential for ALL Patients)

Calcium and Vitamin D Supplementation:

• Calcium: 1,200 mg daily (for women 51-70 years)
• Vitamin D: 800 IU daily (for women 71+ years; 600 IU acceptable for 51-70 years)
• Target serum vitamin D level: ≥20 ng/mL 1

Lifestyle Modifications:

• Weight-bearing exercise: Walking, jogging, stair climbing
• Resistance training: Free weights or resistance bands targeting major muscle groups, 2-3 days/week 3
• Balance training: Tai chi or specific balance exercises to reduce fall risk
• Smoking cessation (if applicable)
• Limit alcohol intake to ≤2 drinks per day 1

Fall Prevention Strategies:

• Home safety assessment (remove tripping hazards, improve lighting, install grab bars)
• Vision and hearing checks
• Medication review for agents that increase fall risk (sedatives, antihypertensives)
• Consider physical therapy evaluation if gait instability present

Step 3: Surveillance and Monitoring

Repeat DEXA scan in 2 years to monitor bone density trajectory. 4, 5 If bone loss accelerates or additional risk factors develop, reassess treatment thresholds at that time.

Earlier repeat (1 year) if:

• New risk factors emerge (glucocorticoid therapy, significant weight loss)
• Clinical concern for accelerated bone loss
• Patient develops symptoms suggestive of fracture

Step 4: Evaluate for Secondary Causes of Osteopenia

While not requiring immediate treatment, ensure evaluation for reversible causes:

• Laboratory assessment: Serum calcium, phosphorus, alkaline phosphatase, 25-hydroxyvitamin D, TSH, complete blood count, creatinine
• Consider: Celiac screening, parathyroid hormone if hypercalcemia present
• Review medications: Glucocorticoids, proton pump inhibitors, anticonvulsants, aromatase inhibitors

Common Pitfalls to Avoid

Do not treat based solely on T-score in the osteopenic range without meeting FRAX thresholds. The evidence for bisphosphonate benefit in osteopenia exists primarily for women with T-scores near -2.5 (advanced osteopenia), not -1.7. 6 Treating this patient would expose her to potential adverse effects (atypical femoral fractures, osteonecrosis of the jaw) without clear benefit given her low absolute fracture risk.

Do not ignore the trabecular bone degradation noted on the femoral neck. While this finding doesn't change immediate management, it emphasizes the importance of non-pharmacologic interventions and surveillance.

Recognize that normal Z-scores (-0.1 at femoral neck, 0.9 at lumbar spine, 1.1 at total hip) indicate her bone density is appropriate for her age. This suggests she is not experiencing accelerated bone loss compared to peers.

When to Reconsider Pharmacologic Treatment

Initiate bisphosphonate therapy if any of the following develop:

• FRAX scores increase to meet treatment thresholds (hip fracture ≥3% or major osteoporotic fracture ≥20%)
• T-score declines to ≤-2.5 (osteoporosis range)
• Fragility fracture occurs (fracture from standing height or less)
• Significant bone loss on follow-up DEXA (>3-5% at spine or hip, exceeding least significant change)
• High-risk medications initiated (e.g., chronic glucocorticoids ≥5 mg prednisone daily for ≥3 months)

If treatment becomes indicated, first-line therapy would be oral bisphosphonates (alendronate 70 mg weekly or risedronate 35 mg weekly), selected based on patient preference and tolerability. 1, 7

Patient Education Points

Counsel the patient that:

• Her bone density shows osteopenia (mild bone thinning) but not osteoporosis
• Her fracture risk over the next 10 years is low (5.7% for major fractures, 0.8% for hip fracture)
• Medication is not currently needed, but lifestyle measures are critical
• Regular monitoring will detect any worsening that might require treatment
• She should report any fractures immediately, even from minor trauma